Gene-editing technique to treat lung cancer is due to be tested in people in August
Chinese scientists are on the verge of being first in the world to inject people with cells modified using the CRISPR–Cas9 gene-editing technique.
A team led by Lu You, an oncologist at Sichuan University’s West China Hospital in Chengdu, plans to start testing such cells in people with lung cancer next month. The clinical trial received ethical approval from the hospital’s review board on July 6.
“It’s an exciting step forward,” says Carl June, a clinical researcher in immunotherapy at the University of Pennsylvania in Philadelphia.
There have been a number of human clinical trials using an alternative gene-editing technique, including one led by June, that have helped patients combat HIV. June is also a scientific adviser on a planned US trial that would also use CRISPR–Cas9-modified cells for the treatment of cancer.
Last month, an advisory panel of the US National Institutes of Health (NIH) approved that project. But the trial also requires a green light from the US Food and Drug Administration (FDA) and a university review board. The US researchers have said they could start their clinical trial by the end of this year.
The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed. “Treatment options are very limited,” says Lu. “This technique is of great promise in bringing benefits to patients, especially the cancer patients whom we treat every day.”
The Latest on: CRISPR
via Google News
The Latest on: CRISPR
- Infecting gut microbes with CRISPR-loaded virus demonstrates potential for microbiome gene editingon November 24, 2021 at 6:33 am
In a first, researchers at the UC San Francisco have successfully used the DNA-editing system, CRISPR to alter the genomes of bacteria living in the guts of mammals, a development which stands to ...
- Op-Ed: Huntington’s key protein mhTT — Best way for CRISPR to prove what it can do?on November 23, 2021 at 8:30 am
Huntington’s Disease is a hideous progressive disease. One of the primary causes is a mutant protein called mhTT, which is a corrupted essential protein in spinal fluid. mhTT replaces the proper ...
- CRISPR Therapeutics to Participate in Upcoming Investor Conferenceson November 23, 2021 at 5:30 am
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team ...
- Using CRISPR for therapeutic drug discoveryon November 21, 2021 at 12:09 pm
Elmar Nurmemmedov uses CRISPR in his research focussing on therapeutic drug discovery and testing these in a disease model.
- Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?on November 21, 2021 at 8:44 am
The gene-editing approach used by Intellia and CRISPR Therapeutics could lead to off-target mutations. Neither company has reported these safety issues in their clinical testing so far. However, both ...
- New insights on the link between CRISPR, p53 gene and mutated cancer cellson November 18, 2021 at 6:22 pm
A protein that protects cells from DNA damage, p53, is activated during gene editing using the CRISPR technique.
- New findings on the link between CRISPR gene-editing and mutated cancer cellson November 18, 2021 at 7:28 am
A protein that protects cells from DNA damage, p53, is activated during gene editing using the CRISPR technique. Consequently, cells with mutated p53 have a survival advantage, which can cause cancer.
- CRISPR and the Climateon November 17, 2021 at 3:07 pm
Earlier this month, the much-anticipated UN Climate Change Conference came to an end. As part of the flurry of activity, the United States and the United Arab Emirates launched the Agriculture ...
- CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy Drugon November 17, 2021 at 6:45 am
CRISPR Therapeutics CRSP, along with partner ViaCyte, announced that Health Canada has approved the clinical trial application for its investigational allogeneic stem cell-derived therapy, VCTX210.
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabeteson November 16, 2021 at 5:30 am
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicin ...
via Bing News